Aardvark Therapeutics
AARD | NASDAQ
$1.26
-$0.07 (-5.26%)
At close: Nov 16, 2026, 4:00 PM ET
$1.21
-$0.05 (-4.22%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Aardvark Therapeutics Company Profile
Company profile explainedCompany Profile
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Bryan Jones | Chief Executive Officer of Ardia |
| Tien-Li Lee | CEO, Secretary & Chairman |
| Derrick C. Li | Chief Business Officer |
| Dvorit Samid | Executive Vice President of Medical Affairs |
| Justin T. Stege | VP and Head of Project Management & Strategy |
| Manasi Sinha Jaiman | Chief Medical Officer |
| Nelson Sun | CFO & COO |
| Ron Lewis | Vice President & Head of CMC |
| Zhenhuan Zheng | Chief Research Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 23, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 08, 2026 | 4 | Filing |
| Oct 08, 2026 | 3 | Filing |
| Oct 08, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
Aardvark Therapeutics
| Country | United States |
| IPO Date | Feb 13, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Tien-Li Lee |
Contact Details
4370 La Jolla Village Drive San Diego,
California 92122 United States
Stock Details
| Ticker Symbol | AARD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001774857 |
| CUSIP Number | 002942100 |
| ISIN Number | US0029421007 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove AARD